Robert Ross joins Surface Oncology as chief medical officer

pharmafile | December 19, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Surface Oncology, bluebirdbio 

Surface Oncology, an immuno-oncology company developing immunotherapies that target the tumour microenvironment, has announced the appointment of Robert Ross as its new chief medical officer. In his new role, he will be responsible for helping to progress its development programs. Particularly, there will be a focus on Surface Oncology’s leading potential drug, SRF231, and bringing this treatment to clinical trial.

Robert Ross joins the Surface Oncology team after numerous working experiences across a range of companies. He joins after spending four years at bluebirdbio, as Vice President of clinical development. Prior to this he also worked in the same role at Infinity Pharmaceuticals and as a clinical scientist at Genentech.

“Immune therapy is the future of oncology treatment. In the last five years, with the introduction of immune system modulation, the lives of patients have been fundamentally changed, but there is clearly more work to do to bring more cures to patients,” said Dr. Ross, speaking on his appointment. “Surface Oncology’s strategy targeting the various components of the tumour microenvironment has an excellent chance of achieving that goal. I look forward to working closely with this outstanding team to move their programs to the clinic as rapidly as possible.”

“The addition of such a well-respected and experienced professional to our team positions us well as we continue to expand our pipeline and advance novel programs into the clinic,” said Detlev Biniszkiewicz, president and CEO of Surface Oncology. “Rob has extensive experience building strong teams and leading early stage development programs into late stage clinical development. We are excited he will be applying these skills at Surface to help achieve our goal of bringing cures to patients.”

Related Content


Novartis expands immuno-oncology programme

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with …

Latest content